WNT3A and hepatocellular carcinoma: Furthermore, SAF-AuNPs/DOX-AuNPs combination therapy showed a more significant decrease in Wnt-3a level in the liver by 72.16% (p < 0.001) as compared to the HCC group (Fig. 6).